NCT07512583 2026-04-06
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
14 trialsNCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT05584800 2026-01-05
Study of ZGGS18 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT06938880 2026-01-05
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT07298772 2025-12-23
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07083323 2025-11-25
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT05170958 2025-05-22
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT05438329 2025-02-27
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT06038396 2025-01-29
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT05205850 2025-01-27
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT06008366 2023-09-13
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT06008379 2023-09-13
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown